

Arab Center for Pharmaceutical
& Chemical Industries Co
Public Shareholding Company
Amman – The Hashemite Kingdom of Jordan

Interim Condensed Financial Statements
and Independent Auditor's Report
for the three months ended March 31, 2025

/

Arab Center For Pharmaceutical
& Chemical Industries Co
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan

Index

	<u>Page</u>
Report on review of interim condensed financial information	-
Interim condensed statement of financial position as at March 31, 2025 (reviewed and unaudited)	1
Interim condensed statement of comprehensive income for the three months ended March 31, 2025 (reviewed and unaudited)	2
Interim condensed statement of changes in equity for the three months ended March 31, 2025 - (reviewed and unaudited)	3
Interim condensed statement of cash flows for the three months ended March 31, 2025 - (reviewed and unaudited)	4
Notes to the interim condensed financial information for the three months ended March 31, 2025	5-7

105181287

Report on review of interim condensed financial information

To Messrs. Shareholders
Arab Center for Pharmaceutical & Chemical Industries Co
Public Shareholding Company
Amman – The Hashemite Kingdom of Jordan

Introduction

We have reviewed the interim condensed statement of financial position of Arab Center for Pharmaceutical & Chemical Industries Co. (Public Shareholding Company) as at March 31, 2025, and the interim condensed statements of comprehensive income, changes in equity and cash flows for the three months then ended. Management is responsible for the preparation and fair representation of this interim financial information in accordance with International Accounting Standard IAS (34) "Interim financial reporting". Our responsibility is to express a conclusion about this interim financial information based on our review.

Scope of Review

We conducted our review in accordance with International Standard on Review Engagement no. (2410) "Review of interim financial information performed by the independent auditor of the entity". A review of consolidated interim condensed financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with International Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Conclusion

Based on our review, nothing has come to our attention that causes us to believe that the accompanying consolidated interim condensed financial information is not prepared, in all material respects, in accordance with International Financial Reporting Standard no. (34) "Interim Financial Reporting".

Significant doubt to continue as a going concern

We would like to emphasize what is stated in the financial statements where the company's accumulated losses amounted to JD 8,830,614 which represents 177% of its capital as at March 31, 2025, the company's total current liabilities exceeded its current assets by an amount of JD 2,708,387, these matters cast significant doubt on the company ability to continue as a going concern, and its continuance dependent on providing for necessary funding it to pay its liabilities and its success of its operations in the future where the company submitted a integrated plan to the company's continuing.

- Ending the dispute with the contractor as quickly as possible, then completing the final stages of the expansion project and starting actual production on the new lines, which will lead to the restoration of traditional markets in addition to opening new markets.





Report on review of interim condensed financial information for the three months ended March 31, 2025


- The general assembly held an extraordinary meeting dated April 29, 2023 and the following decisions were made:
 - Decrease the company capital by quenching the amount of JD 4,500,000 from the accumulated losses as at December 31, 2021 in the authorized capital and the paid-in capital to become JD 500,000.
 - Extinguish part of accumulated losses through statutory reserves amounting JD 1,138,105.
 - Increase the capital of the company by an amount of JD 4,500,000 to become JD 5,000,000 instead of a JD 500,000 through private subscription and delegate the Board of Directors in this regard.
 - Balance of Mr. Hamzah Tantash amounting JD 2,612,914.
 - Balance of Tantash Group amounting JD 1,529,542.
 - Balance of Mr. Mazen Tantash amounting JD 357,544.

The legal requirements were not completed regarding the decision of extraordinary general assembly till the date of the financial statements report.

Emphasis of matter

- We would like to state that there are restrains on the lands, buildings, vehicles and current accounts at banks, in addition to a restrain on the company's registration as shown in the company's registration certificate issued by the Ministry of Industry and Trade-Companies Control Department.
- We would like to refer to note (3) the project under construction which started on March 2013 is still not complete till the date of the financial statements, knowing that the disputes with contractor at the arbitration committee to adjudicate upon the dispute.

Talal Abu-Ghazaleh & Co. International



Mohammad Al-Azraq
(License # 1000)

Amman April 24, 2025

Arab Center For Pharmaceutical
& Chemical Industries Co
Public Shareholding Company
Amman – The Hashemite Kingdom of Jordan

Interim condensed statement of financial position as at March 31, 2025 – (Reviewed and unaudited)

		March 31,2025	December 31,2024
	Notes	(Reviewed and unaudited)	(Audited)
		JD	JD
ASSETS			
Non-current Assets			
Property, plant and equipment	3	4,439,374	4,445,120
Investments in an associate	4	-	-
Investment in financial asset at fair value through other comprehensive income		1	1
Due from related party		5,542	5,542
Total Non-Current Assets		<u>4,444,917</u>	<u>4,450,663</u>
Current Assets			
Inventory		89,559	83,363
Other debit balances		86,835	91,170
Trade receivables		1,169	1,836
Cash in hand		462	-
Total Current Assets		<u>178,025</u>	<u>176,369</u>
TOTAL ASSETS		<u><u>4,622,942</u></u>	<u><u>4,627,032</u></u>
EQUITY AND LIABILITIES			
Equity			
Declared and paid-in capital		5,000,000	5,000,000
Statutory reserve		1,138,105	1,138,105
Change in fair value of investments in financial assets at fair value through other comprehensive income		(115,457)	(115,457)
Accumulated losses	5	(8,830,614)	(8,829,316)
Deficit in Equity		<u>(2,807,966)</u>	<u>(2,806,668)</u>
Liabilities			
Non Current Liabilities			
Shareholders payable		4,544,496	4,544,496
Current Liabilities			
Other credit balances		878,797	882,563
Trade payables		411,676	416,443
Due to related parties		1,595,939	1,590,198
Total Current Liabilities		<u>2,886,412</u>	<u>2,889,204</u>
Total Liabilities		<u>7,430,908</u>	<u>7,433,700</u>
TOTAL EQUITY AND LIABILITIES		<u><u>4,622,942</u></u>	<u><u>4,627,032</u></u>

The attached notes constitute an integral part of these Interim Condensed Financial Statements

Arab Center For Pharmaceutical
& Chemical Industries Co
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan

Interim condensed statement of comprehensive income for the three months ended March 31, 2025
- (Reviewed and unaudited)

	March 31, 2025	March 31, 2024
	JD	JD
Sales	33,219	41,070
Cost of sales	<u>(26,306)</u>	<u>(31,361)</u>
Gross profit	6,913	9,709
Other revenues, net	6,825	4,995
Administrative expenses	<u>(15,036)</u>	<u>(16,701)</u>
Loss	<u><u>(1,298)</u></u>	<u><u>(1,997)</u></u>
Weighted average number of shares	<u>5,000,000</u>	<u>5,000,000</u>
Loss per share	<u><u>JD (-/0003)</u></u>	<u><u>JD (-/0004)</u></u>

The attached notes constitute an integral part of these Interim Condensed Financial Statements

Arab Center For Pharmaceutical
& Chemical Industries Co
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan

Interim condensed statement of changes in equity for the three months ended March 31, 2025 - (Reviewed and unaudited)

	Capital	Statutory reserve	Change in fair value of investments in financial assets at fair value through other comprehensive income	Accumulated losses	Total
Balance as at March 31, 2025	JD	JD	JD	JD	JD
Balance as at January 1, 2025	5,000,000	1,138,105	(115,457)	(8,829,316)	(2,806,668)
Loss	-	-	-	(1,298)	(1,298)
Balance as at March 31, 2025	5,000,000	1,138,105	(115,457)	(8,830,614)	(2,807,966)
Balance as at March 31, 2024					
Balance at January 1, 2024	5,000,000	1,138,105	(115,457)	(8,401,920)	(2,379,272)
Loss	-	-	-	(1,997)	(1,997)
Balance as at March 31, 2024	5,000,000	1,138,105	(115,457)	(8,403,917)	(2,381,269)

The attached notes constitute an integral part of these Interim Condensed Financial Statements

Arab Center For Pharmaceutical
& Chemical Industries Co
Public Shareholding Company
Amman – The Hashemite Kingdom of Jordan

Interim condensed statement of cash flows for the three months ended March 31, 2025
– (Reviewed and unaudited)

	March 31, 2025	March 31, 2024
	JD	JD
CASH FLOWS FROM OPERATING ACTIVITIES		
Loss	(1,298)	(1,997)
Adjustments for :		
Depreciation	5,746	5,974
Change in operating assets and liabilities:		
Due from related party	-	2,705
Inventory	(6,196)	(21,743)
Other debit balances	4,335	(465)
Trade receivables	667	(781)
Other credit balances	(3,766)	14,946
Trade payables	(4,767)	6,487
Net cash from operating activities	(5,279)	5,126
CASH FLOWS FROM FINANCING ACTIVITIES		
Shareholders payable	-	199
Due to related parties	5,741	(2,829)
Net cash from financing activities	5,741	(2,630)
Net change in cash and cash equivalents	462	2,496
Cash and cash equivalents - beginning of period	-	17,623
Cash and cash equivalents - end of period	462	20,119

The attached notes constitute an integral part of these Interim Condensed Financial Statements

Arab Center For Pharmaceutical
& Chemical Industries Co
Public Shareholding Company
Amman - The Hashemite Kingdom of Jordan

Notes to the interim condensed financial statements

1. Legal status and activity

- The Company was established on July 5, 1983 and registered as a public shareholding company with the Ministry of Industry and Trade under the number (185).
- The main Company's activities are as follows:
 - Human liquid medication manufacturing
 - Human pills medication manufacturing
 - Human suppositories medication manufacturing
 - Veterinarian antibiotics manufacturing
 - Veterinarian antibacterial manufacturing
 - Veterinarian vitamins manufacturing
 - Gelatin capsules manufacturing
- The financial statements were approved by the Company's board of directors in its session held on April 23, 2025.
- There is restrain on the company due to the existence of executive legal cases on the company.

2. Financial statements preparation framework and material accounting policies

- The interim condensed financial information for the company were prepared according to the International Accounting Standard (34) "Interim Financial Reporting".
- Accounting policies used in preparing the interim condensed financial statement are consistent with those policies used in preparing the financial statements for the year ended December 31, 2024.

Notes to the interim condensed financial statements for the three months ended March 31, 2025

3. Property, plant and equipment

March 31, 2025	Lands (*)	Buildings (*)	Devices and machinery	Furniture and decorations	Electrical devices and condition units	Equipment and tools	Vehicles (*)	Computer hardware and software	Projects under construction (**)	Total
	JD	JD	JD	JD	JD		JD	JD	JD	JD
Cost										
Beginning of period balance	322,476	1,216,723	3,358,832	208,255	114,481	27,007	36,582	200,705	3,660,240	9,145,301
End of period balance	322,476	1,216,723	3,358,832	208,255	114,481	27,007	36,582	200,705	3,660,240	9,145,301
Accumulated depreciation										
Beginning of period balance	-	755,630	3,358,133	207,829	114,410	27,002	36,579	200,598	-	4,700,181
Depreciation	-	5,746	-	-	-	-	-	-	-	5,746
End of period balance	-	761,376	3,358,133	207,829	114,410	27,002	36,579	200,598	-	4,705,927
Net	322,476	455,347	699	426	71	5	3	107	3,660,240	4,439,374
December 31, 2024										
Cost										
Beginning of year balance	322,476	1,216,723	3,358,832	208,255	114,481	27,007	36,582	200,705	3,660,240	9,145,301
End of year balance	322,476	1,216,723	3,358,832	208,255	114,481	27,007	36,582	200,705	3,660,240	9,145,301
Accumulated depreciation										
Beginning of year balance	-	732,262	3,358,106	207,771	114,410	27,002	36,579	200,598	-	4,676,728
Depreciation	-	23,368	27	58	-	-	-	-	-	23,453
End of year balance	-	755,630	3,358,133	207,829	114,410	27,002	36,579	200,598	-	4,700,181
Net	322,476	461,093	699	426	71	5	3	107	3,660,240	4,445,120

(*) Lands, buildings, vehicles and machinery are seized against legal cases held at related courts, and is still outstanding as of the date of the financial statements.

(**) Projects under construction represent the company's building and facilities development and improvement efforts, in addition to buying machinery and equipment in order to increase the production capacity to replace certain production lines, and to improve the facility's infrastructure to match conditions of the drug production process as started in March 2013.

Notes to the interim condensed financial statements for the three months ended March 31, 2025

4. Investment in an associate

Company name	Country of incorporation	Legal entity	Ownership	Total Assets	Total Liabilities	Profit	Accumulated losses
			%	JD	JD	JD	
Middle East Pharmaceutical and Chemical Industries and Medical Appliances Company	Jordan	P.L.C	12.85	7,796,541	8,870,870	(348,052)	(7,484,914)

(*) Movement of investment through the period/year was as the follows:

	March 31, 2025	December 31, 2024
	JD	JD
Cost	394,016	51,573
Share of results of associate	(394,016)	(51,573)
Net	-	-

5. Accumulated losses

The company's accumulated losses amounted to JD 8,830,614 which represents 177% of its capital as at March 31, 2025, follows a summary of the company's plan:

- End the conflict with the contractor as soon as possible and then complete the final stages of the expansion project and the start of the actual production process on the new lines, and this leads to re-entry into the traditional markets and opening new markets.
- The general assembly held an extraordinary meeting on March 29, 2023 and the following decisions were made:
 - Decreasing the company's capital by quenching the amount of JD 4,500,000 000 from the accumulated losses as of December 31, 2021 so the capital and the paid-in capital become JD 500,000.
 - Amortize part of the accumulated losses through statutory reserve amounting to JD 1,138,105.
 - Increase the capital of the company by an amount of JD 4,500, to become JD 5,000,000 instead of JD 500,000 by capitalizing part of the company's liabilities as follows:
 - Balance of Mr. Hamzah Tantash amounting JD 2,612,914.
 - Balance of Tantash Group amounting JD 1,529,542.
 - Balance of Mr. Mazen Tantash amounting JD 357,544.
- The extraordinary meeting of the general assembly decisions has not been executed until the date of the interim condensed statements.

6. The potential effects of economic fluctuations

As a result of the current global conflict, where the entity has taken into account any possible impact of current economic fluctuations in the inputs of future macroeconomic factors when determining the severity and probability of economic scenarios to determine expected credit losses.